ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 multi-center trial designed to evaluate the clinical efficacy and safety of
VIVITROL® (Medisorb® naltrexone 380 mg) versus placebo when administered to adults upon
discharge from inpatient treatment for opioid dependence.
The study was conducted in 2 parts, Part A and Part B. The clinical portion of both parts has
completed. Results for Part B are not yet available.